Arizona State Retirement System lifted its stake in Regenxbio Inc (NASDAQ:RGNX) by 8.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 46,362 shares of the biotechnology company’s stock after purchasing an additional 3,744 shares during the quarter. Arizona State Retirement System’s holdings in Regenxbio were worth $1,945,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Regenxbio by 51.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,805,969 shares of the biotechnology company’s stock valued at $211,851,000 after purchasing an additional 947,671 shares during the period. MetLife Investment Advisors LLC boosted its position in shares of Regenxbio by 66.9% in the 3rd quarter. MetLife Investment Advisors LLC now owns 22,065 shares of the biotechnology company’s stock valued at $1,666,000 after purchasing an additional 8,848 shares during the period. Northern Trust Corp boosted its position in Regenxbio by 21.2% during the 2nd quarter. Northern Trust Corp now owns 359,040 shares of the biotechnology company’s stock worth $25,762,000 after acquiring an additional 62,849 shares during the period. Jane Street Group LLC acquired a new stake in Regenxbio during the 3rd quarter worth about $837,000. Finally, Shell Asset Management Co. acquired a new stake in Regenxbio during the 3rd quarter worth about $392,000. Institutional investors and hedge funds own 80.55% of the company’s stock.

In other news, CFO Vittal Vasista sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 17th. The stock was sold at an average price of $46.35, for a total transaction of $347,625.00. Following the completion of the sale, the chief financial officer now directly owns 125,683 shares of the company’s stock, valued at approximately $5,825,407.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Curran Simpson sold 43,832 shares of the firm’s stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $50.08, for a total value of $2,195,106.56. Following the sale, the senior vice president now directly owns 47,950 shares of the company’s stock, valued at $2,401,336. The disclosure for this sale can be found here. Insiders have sold a total of 241,211 shares of company stock valued at $13,832,632 over the last ninety days. Company insiders own 16.90% of the company’s stock.

Shares of NASDAQ RGNX opened at $45.37 on Thursday. Regenxbio Inc has a one year low of $26.14 and a one year high of $85.10. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -18.52 and a beta of 0.41.

RGNX has been the subject of a number of research reports. ValuEngine lowered Regenxbio from a “buy” rating to a “hold” rating in a research report on Wednesday, December 5th. Leerink Swann initiated coverage on Regenxbio in a research report on Tuesday, November 27th. They set an “underperform” rating and a $42.00 price objective for the company. Barclays raised their price objective on Regenxbio from $83.00 to $88.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 18th. BidaskClub lowered Regenxbio from a “hold” rating to a “sell” rating in a research report on Saturday, December 8th. Finally, Chardan Capital restated a “buy” rating and set a $127.50 price objective on shares of Regenxbio in a research report on Friday, January 4th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $81.50.

WARNING: “Regenxbio Inc (RGNX) Position Boosted by Arizona State Retirement System” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/regenxbio-inc-rgnx-position-boosted-by-arizona-state-retirement-system/2819189.html.

Regenxbio Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Story: Options Trading

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.